The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Oxford University to Study Adalimumab as Potential COVID-19 Treatment

Oxford University to Study Adalimumab as Potential COVID-19 Treatment

September 30, 2020 • By Josephine Mason & Kate Kelland

  • Tweet
  • Email
Print-Friendly Version / Save PDF

LONDON (Reuters)—Oxford University said on Wednesday it will study whether the prescription medicine, adalimumab (Humira), is an effective treatment for COVID-19 patients—the latest effort to repurpose existing drugs as potential coronavirus therapies.

You Might Also Like
  • Sanofi, Regeneron Expand Testing of Potential Coronavirus Treatment
  • Tocilizumab Fails to Help COVID-19 Patients in Italian Study
  • Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19

Adalimumab, which is sold by AbbVie, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Recent studies have shown that COVID-19 patients already taking anti-TNF drugs for inflammatory bowel disease and inflammatory arthritis are less likely to be admitted to hospital, Oxford says in a statement.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Oxford’s trial, called AVID-CC, will be aimed at treating people in the community, especially in care homes, the university said. It will enroll up to 750 patients from community care settings throughout Britain.

Humira is used to treat a range of conditions including rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriasis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The availability of biosimilar versions of the medicine would make it affordable and accessible if the trial is successful, Oxford says. Novartis makes one of the alternatives, adalimumab-adaz (Hyrimoz).

Research has identified some treatments for hospitalized COVID-19 patients, including Gilead’s remdesivir, as well as the generic steroid drug dexamethasone.

Researchers have also studied other anti-inflammatory drugs for treating COVID-19. Severe infections are believed to be triggered by an over-reaction of the immune system, known as a cytokine storm, and drugs that suppress certain elements of the immune system can play a role in arresting a rapid escalation of symptoms.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

But there are as yet no effective therapies for people who are not admitted to hospital.

Care homes were particularly hard hit by the first wave of COVID-19 in the U.K. and other countries. If adalimumab were successful against COVID-19, this could help some older people who are some of most vulnerable, it said, at a time when governments are struggling to contain the pandemic.

The Oxford study is funded by the COVID-19 Therapeutics Accelerator initiative set up by global health charity Wellcome, as well as the Bill and Melinda Gates Foundation and Mastercard.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: adalimumab, COVID-19

You Might Also Like:
  • Sanofi, Regeneron Expand Testing of Potential Coronavirus Treatment
  • Tocilizumab Fails to Help COVID-19 Patients in Italian Study
  • Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19
  • Trial of Gilead’s Potential Coronavirus Treatment Running Ahead of Schedule

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)